Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1273.712 vaccine cardiac troponin study in adolescents and young adults
NCT06634797Phase 4Completed
- Sponsor
- Moderna Inc
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of mRNA-1273.712 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Moderna Inc. Primary endpoint: Number of Participants With Elevated Cardiac Troponin I at Day 4 or Day 32 (3 Days After Injection 1 or Injection 2). Started Oct 2024; status: completed.
02
Drugs
mRNA-1273.712
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06634797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06634797.